Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05144841 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
A Phase 2 study of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT05144841: Active Phase 2 study of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, sponsored by Merck Sharp & Dohme.
NCT05144841 is a Phase 2 study of Relapsed or Refractory Diffuse Large B-Cell Lymphoma that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 140 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05144841, a Phase 2 study of Relapsed or Refractory Diffuse Large B-Cell Lymphoma, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Primary Outcome
ORR is percentage of participants with complete response (CR) or partial response (PR). ORR by cohort, relapsed or refractory (rr) DLBCL as assessed by BICR according to Lugano Response Criteria 2014 in participants treated with zilovertamab vedotin Q3W. CR is the complete radiologic response. PR is a partial response, \>=50% decrease in sum of the product of the perpendicular diameters for multiple lesions for up to 6 target measurable nodes and extranodal sites.
Conditions Studied
Interventions
- BIOLOGICAL Zilovertamab vedotin
Study Locations (20)
Ohio
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0217) - Cincinnati
- University Hospitals Cleveland Medical Center ( Site 0222) - Cleveland
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C - Columbus
California
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0229) - Orange
- Innovative Clinical Research Institute ( Site 0202) - Whittier
Michigan
- University of Michigan ( Site 0200) - Ann Arbor
- Karmanos Cancer Institute ( Site 0216) - Detroit
District of Columbia
- Georgetown University Medical Center ( Site 0204) - Washington D.C.
Georgia
- Northside Hospital ( Site 0206) - Atlanta
Illinois
- University of Chicago Medical Center ( Site 0207) - Chicago
Indiana
- Franciscan St. Francis Health ( Site 0225) - Indianapolis
Maryland
- University of Maryland-Greenebaum Comprehensive Cancer Center ( Site 0211) - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2022-01-08 |
| Est. Completion | 2026-04-22 |
| Phase | Phase 2 |
What the registry record for NCT05144841 still lists
NCT05144841 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 1 condition, with Relapsed or Refractory Diffuse Large B-Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Zilovertamab vedotin is the first listed.
NCT05144841 names 20 study sites across 16 states, led by Ohio, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT05144841 about?
NCT05144841 is a clinical study titled "A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)". The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventi...
What is the current status of trial NCT05144841?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2022-01-08. Estimated completion is 2026-04-22.
What conditions does trial NCT05144841 study?
This clinical trial studies the following conditions: Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
What interventions are being tested in trial NCT05144841?
The interventions under investigation include: Zilovertamab vedotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT05144841?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05144841 being conducted?
This trial has 20 study locations across California, District of Columbia, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05144841's enrollment target sits among peer trials
140 512th of 2000 higher than 1,476 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI